Inkang Life debuts AI-powered sample aliquoting, extraction and purification workstation DreamFlow·E at CIIE
Inkang Life, a subsidiary of Haier Group, debuted and first showcased the AI-powered sample aliquoting, extraction and purification workstation (DreamFlow·E) at this year's CIIE. Users need only state their experimental requirements, and the AI can autonomously design the experimental workflow; after simulation verification, it commands a robotic arm to complete operations such as separation, extraction and purification. Some exhibitors have already signed letters of intent to purchase. This year, Inkang Life brought more than 40 innovative achievements, over 60% of which are debuts and first showcases, and released the "1+3+X" AI strategic blueprint. Its life and health large model IncGPT has completed filing. Currently, its products and services cover more than 160 countries and regions.
Body · AI translation
At the medical equipment and healthcare exhibition area of this year's China International Import Expo (CIIE), a scene at the booth of Yingkang Life, the big health ecosystem brand under Haier Group, drew many visitors to stop and watch: inside a sample pre-processing workstation, a suspended robotic arm shuttled nimbly among different functional zones, scheduling samples to complete experimental operations such as separation, extraction and purification. The entire process required no step-by-step manual operation by researchers; one only needed to state the experimental requirements, and AI (artificial intelligence) could autonomously design the experimental workflow, and after simulation verification, direct the robotic arm and various functional modules to work together to complete the experiment.
"This is the AI+ sample aliquoting, extraction and purification workstation (DreamFlow·E) that we are unveiling and exhibiting for the first time at this year's CIIE," said Cao Jinghui, Director of Digital-Intelligent Sample Industry Automation R&D at Haier Biomedical, which is under Yingkang Life. Compared with traditional manual operation, this device has higher sample pre-processing efficiency, can also reduce variations caused by human operation, improve the consistency of sample processing, and enable full traceability of the experimental process. Targeting different experimental needs, the device can flexibly be configured with functional modules such as filtration, automatic cap opening and closing, code scanning identification and pipetting, to achieve automated extraction of different components such as plasma and buffy coat, providing support for cohort studies, immunology research and exploration of disease mechanisms.
"Since the opening of this year's CIIE, several groups of business clients have come to inquire every day, showing strong interest in cooperation, and some clients have already signed letters of purchase intent," Cao Jinghui said.
The CIIE is both a debut stage for global new products and a booster for the implementation of industrial innovation. Yingkang Life has attended the CIIE for seven consecutive years. This year, it brought more than 40 innovative achievements, over 60 percent of which are debuts and first exhibitions, centrally presenting the collaborative practices of its three major industries—life sciences, clinical medicine and biopharmaceuticals—empowering multi-scenario solutions with AI and demonstrating a closed-loop industrial ecosystem of "basic research—clinical validation—drug development."
At this year's CIIE, Yingkang Life also released its "1+3+X" AI strategic blueprint and latest achievements. According to the introduction, the life and health large model IncGPT independently developed by Yingkang Life has completed filing, and the AI agent "Xiaoying" has cumulatively formed nearly a thousand AI-native applications, becoming an intelligent partner connecting laboratories, hospitals and homes.
In recent years, Yingkang Life has innovated the AI+ proactive health management platform to promote the expansion of quality medical resources to lower levels; addressing unmet treatment needs, the SR604 injection has completed registration for Phase III clinical trials for the indication of bleeding prevention in hemophilia A/B, exploring new preventive treatment options for patients; promoting an increase in the conversion rate of medical scientific and technological achievements, linking industry, academia and research, and jointly building the medical-engineering technology innovation industrialization platform "Haiyihui," which has cumulatively promoted the transformation of 25 innovative technologies.
"The CIIE is an important window for us to observe global trends and connect with ecosystem partners," said Zhang Dandan, Brand General Manager of Yingkang Life. "Taking the CIIE as an opportunity, we will continue to integrate AI innovation and open co-creation into the global public health system and contribute to building a global community of health for all." At present, Yingkang Life's products and services have covered more than 160 countries and regions, benefiting hundreds of millions of users cumulatively.